2
Announcements
Trials
Browse
Landscape
Status
Completed
17
Terminated
13
Active not recruiting
10
Recruiting
8
Unknown
7
Withdrawn
4
Not yet recruiting
2
Suspended
1
No longer available
1
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Afatinib
3
3-Iodobenzylguanidine
3
niraparib
2
lenvatinib
2
ibrutinib
2
gallium 68 PSMA-11
2
abemaciclib
2
Trastuzumab
2
Sunitinib
2
Ramucirumab
2
Oxaliplatin
2
Magnetic Resonance Spectroscopy
2
Gefitinib
2
Fluorouracil
2
Capecitabine
2
Amifampridine
2
Abiraterone Acetate
2
zenocutuzumab
1
vorasidenib
1
tucatinib
1
trilaciclib
1
trifluridine tipiracil drug combination
1
tovorafenib
1
talquetamab
1
tafasitamab
1
selpercatinib
1
sacituzumab govitecan
1
ripretinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Approved for marketing
×
ponatinib
×
Clear all
NCT01592136
2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing